StockSelector.com
  Research, Select, & Monitor Tuesday, July 17, 2018 1:58:40 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Cara Therapeutics Inc.$21.16($.56)(2.58%)

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Cara Therapeutics Inc. has an overall rank of 3462 out of 7057 stocks based on 8 positive rankings and 8 negative rankings.

Positive Rankings
Estimated Revenue Growth
Cara Therapeutics Inc. rank is 88
Debt-to-Equity
Cara Therapeutics Inc. rank is 208
90 Day Gain
Cara Therapeutics Inc. rank is 296
Target Prices
The average analysts' target price is $26.00 for Cara Therapeutics Inc. using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Cara Therapeutics Inc. is ranked 302.
10 Day Gain
Cara Therapeutics Inc. rank is 333
Highest Cash Growth
Cara Therapeutics Inc. rank is 345
Low vPut/Call
Cara Therapeutics Inc. has a low Put/Call ratio of 0.33 on active options expiring within the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Cara Therapeutics Inc. is ranked 640.
Low Put/Call
Cara Therapeutics Inc. has a low Put/Call ratio of 0.59 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Cara Therapeutics Inc. is ranked 1273.
Negative Rankings
High/Dropping MACD
The MACD remains positive, but is dropping... suggesting a possible near-term correction. Of companies with a positive, but declining MACD, Cara Therapeutics Inc. is ranked 135.
Overbought RSI
The 14 Day Relative-Strength Index for Cara Therapeutics Inc. is 70.2. An RSI above 70 indicates the stock is overbought. Among companies with a high RSI, Cara Therapeutics Inc. is ranked 214.
Down EPS Surprise
Cara Therapeutics Inc. missed the consensus earnings estimate when it last reported quarterly earnings.
Negative ROA
Cara Therapeutics Inc. rank is 440
Negative ROE
Cara Therapeutics Inc. rank is 473
Price-to-Book
Cara Therapeutics Inc. rank is 574
Negative Revenue Growth
Cara Therapeutics Inc. rank is 681
Overbought Stochastics
Cara Therapeutics Inc. rank is 823







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2018 StockSelector.com. All rights reserved.